
Opinion|Videos|March 1, 2025
Current and Emerging Treatment Landscape of mHSPC
Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Advertisement
Episodes in this series

Timecodes
1:54 mHSPC and Imaging
4:57 Current SOC in mHSPC
10:15 Choosing Therapy in mHSPC
18:51 ARANOTE Trial in mHSPC
21:15 Experience With ARI
27:08 Emerging mHSPC Treatments
32:51 ARANOTE Subgroup Analysis
35:31 Future Outlook for mHSPC
Advertisement
Related to this article

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
PTEN loss: From biomarker to treatment strategy in mHSPC
2
Q&A: Gary Kirsh, MD, on health policy for independent urology
3
Modern BCG outperforms historic benchmarks in high-risk NMIBC
4
Q&A: Suzanne B. Merrill, MD, FACS, on treating high-risk NMIBC
5








